BiomX (PHGE) Cost of Revenue (2026)
BiomX's (PHGE) quarterly Cost of Revenue came in at $235000.0 in Q2 2026.
Powered by 
Analysis
BiomX (PHGE) Cost of Revenue (2026) Analysis & Trends
BiomX has disclosed Cost of Revenue across 1 years of filings, most recently posting $235000.0 for Q2 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cost of Rev (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 2.81 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 1.58 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 489.20 Mn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 360.70 Mn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | 145.00 Mn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 93.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 298.26 Mn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 776.90 Mn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 284,000.00 |
| 10 | BiomX | 17.33 Mn | 16.75 Mn | 97,000.00 | 235,000.00 |